China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
October 07, 2024 16:15 ET
|
China SXT Pharmaceuticals, Inc.
Jiangsu, China, , Oct. 07, 2024 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (“SXTC” or the “Company”), (NASDAQ: SXTC) announced today that on October 3, 2024, the Company received a...
China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq’s Minimum Bid Price Rule
October 26, 2023 16:05 ET
|
China SXT Pharmaceuticals, Inc.
TAIZHOU, China, Oct. 26, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development,...
China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split
October 04, 2023 08:30 ET
|
China SXT Pharmaceuticals, Inc.
TAIZHOU, China, Oct. 04, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development,...
China SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule
May 10, 2023 08:00 ET
|
China SXT Pharmaceuticals, Inc.
TAIZHOU, China, May 10, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development,...
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
November 07, 2022 08:00 ET
|
China SXT Pharmaceuticals, Inc.
Jiangsu, China, Nov. 07, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (“SXTC” or the “Company”), (NASDAQ: SXTC) announced today that on November 3, 2022, the Company received a...
China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split
May 18, 2022 12:30 ET
|
China SXT Pharmaceuticals, Inc.
TAIZHOU, China, May 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research,...
China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million
March 14, 2022 22:33 ET
|
China SXT Pharmaceuticals, Inc.
TAIZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research,...
China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment
January 20, 2022 10:45 ET
|
China SXT Pharmaceuticals, Inc.
TAIZHOU, China, Jan. 20, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development,...
China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares
January 18, 2022 06:47 ET
|
China SXT Pharmaceuticals, Inc.
TAIZHOU, China, Jan. 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research,...
China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares
January 14, 2022 17:43 ET
|
China SXT Pharmaceuticals, Inc.
TAIZHOU, China, Jan. 14, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development,...